Crux Wealth Advisors Sells 86 Shares of Cencora, Inc. $COR

Crux Wealth Advisors trimmed its holdings in shares of Cencora, Inc. (NYSE:COR) by 3.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,101 shares of the company’s stock after selling 86 shares during the quarter. Crux Wealth Advisors’ holdings in Cencora were worth $630,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. GAMMA Investing LLC boosted its position in shares of Cencora by 57.0% during the 1st quarter. GAMMA Investing LLC now owns 5,748 shares of the company’s stock valued at $1,598,000 after acquiring an additional 2,087 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in Cencora by 4.5% in the first quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock valued at $307,000 after purchasing an additional 48 shares in the last quarter. Cornerstone Wealth Management LLC bought a new stake in Cencora during the first quarter valued at approximately $202,000. CWA Asset Management Group LLC grew its stake in Cencora by 9.8% in the 1st quarter. CWA Asset Management Group LLC now owns 1,715 shares of the company’s stock worth $477,000 after buying an additional 153 shares in the last quarter. Finally, Institute for Wealth Management LLC. purchased a new position in Cencora in the 1st quarter worth approximately $229,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

COR has been the topic of several research reports. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Evercore ISI set a $340.00 target price on Cencora in a research note on Wednesday, October 8th. Jefferies Financial Group lifted their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, June 30th. Mizuho upped their price objective on Cencora from $316.00 to $334.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Wells Fargo & Company increased their price objective on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $324.91.

Cencora Stock Up 1.7%

Shares of NYSE:COR opened at $324.83 on Friday. The stock has a market capitalization of $62.98 billion, a P/E ratio of 33.42, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The stock’s 50-day moving average price is $300.30 and its 200-day moving average price is $293.23. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $325.70.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. During the same period in the prior year, the business posted $3.34 EPS. Cencora’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s payout ratio is presently 22.63%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the sale, the chief executive officer owned 39,274 shares of the company’s stock, valued at $11,389,460. This represents a 11.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,025 shares of company stock valued at $14,831,784 over the last quarter. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.